Novavax is trading 5.52% down now at $8.45, with no clear company-specific catalyst identified.

  • No clear company-specific announcement, filing, analyst action, or regulatory catalyst was identified for August 24, 2026.
  • Reuters’ latest Novavax-specific report remains focused on the August 6 revenue outlook increase.
  • The broader market is mixed-to-lower, with Nasdaq down 0.75%, but that does not clearly explain the magnitude of Novavax’s decline.